Corcept Therapeutics Incorporated
0I3Q.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.1B
Close$
$81.70
30.6% downside
Current Fair Value
30.6% downsideOvervalued by 30.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.10 Billion |
|---|---|
| Enterprise Value | $13.01 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.95 |
| Beta | 0.46 |
| Outstanding Shares | 105,377,000 |
Return
| Return on Equity | 7.73% |
|---|---|
| Return on Assets | 6.14% |
| Return on Invested Capital | 2.92% |
Valuation & Multiples
| P/E Ratio | 233.06 |
|---|---|
| PEG | 1071.23 |
| Price to Sales | 16.81 |
| Price to Book Ratio | 19.61 |
| Enterprise Value to Revenue | 15.66 |
| Enterprise Value to EBIT | 605.79 |
| Enterprise Value to Net Income | 238 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$221.15 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.81
Average shareholder expectationRevenue Estimate
$323.90 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Corcept Therapeutics Inc
730 employees
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...